Pharmacogenetics of adverse effects due to antiretroviral drugs.

作者: Viladés C , López-Dupla M , Olona M , Gutiérrez F , Vidal F

DOI:

关键词:

摘要: The availability of highly active antiretroviral therapy has markedly improved the survival rate and quality life in patients infected with HIV. At present, however, there is still no cure for HIV those undergoing treatment have to do so life. use drugs been associated several toxicities that limit their success. Some acute chronic these include hypersensitivity reactions, neurotoxicity, nephropathy, liver damage, appearance body fat redistribution syndrome different metabolic alterations accompany it. are family- or even drug-specific. Since not all take a particular medication develop adverse effect attributed drug, it therefore postulated must be genetically conditioned individual predisposition developing effect. Pharmacogenetics science studies interindividual variations response toxicity pharmaceuticals due genetic composition individuals - other words, how person's make-up influences favorable effects certain treatment. Sufficient advances made this discipline allow fertile field research move out basic laboratory into clinical applications. present article reviews investigations published regarding association between determinants persons resulting from drugs. Special emphasis devoted resulted applications such as pre-screening HLA B*5701 avoiding abacavir-related syndrome.

参考文章(153)
Tomas Cihlar, Genevieve Laflamme, Adrian S Ray, Jennifer E Vela, Gerald R Rhodes, Leah Tong, Anupma Roy, Michael D Fuller, Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antiviral Therapy. ,vol. 12, pp. 267- 272 ,(2007)
Magnus Ingelman-Sundberg, Stefan Lundgren, Filip Josephson, Lars Ståhle, Anders Sönnerborg, Jue Wang, Anders Rane, Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenetics and Genomics. ,vol. 16, pp. 191- 198 ,(2006) , 10.1097/01.FPC.0000189797.03845.90
Amalio Telenti, Philip E Tarr, Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antiviral Therapy. ,vol. 12, pp. 999- 1013 ,(2007)
Heather J Ribaudo, Catia Marzolini, Todd Hulgan, David B Clifford, Richard B Kim, Edward P Acosta, Roy M Gulick, David W Haas, Camlin Tierney, Grant R Wilkinson, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. ,vol. 18, pp. 2391- 2400 ,(2004)
Thomas Lang, Kathrin Klein, Joachim Fischer, Andreas Nussler, Peter Neuhaus, Ute Hofmann, Michel Eichelbaum, Matthias Schwab, Ulrich Zanger, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. ,vol. 11, pp. 399- 415 ,(2001) , 10.1097/00008571-200107000-00004
Elke Störmer, Lisa L. von Moltke, Michael D. Perloff, David J. Greenblatt, Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharmaceutical Research. ,vol. 19, pp. 1038- 1045 ,(2002) , 10.1023/A:1016430825740
Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine. ,vol. 356, pp. 1723- 1735 ,(2007) , 10.1056/NEJMOA062744
Eric Ledru, Névéna Christeff, Olivier Patey, Pierre de Truchis, Jean-Claude Melchior, Marie-Lise Gougeon, None, Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus–associated lipodystrophy syndrome Blood. ,vol. 95, pp. 3191- 3198 ,(2000) , 10.1182/BLOOD.V95.10.3191
Mar Masiá, Félix Gutiérrez, Sergio Padilla, José M Ramos, Javier Pascual, None, Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine? Journal of Acquired Immune Deficiency Syndromes. ,vol. 35, pp. 427- 428 ,(2004) , 10.1097/00126334-200404010-00013